Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRA vs METROCREAM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Type 2 diabetes mellitus,Polycystic ovary syndrome (off-label)
Rosacea (inflammatory papules and pustules),Topical treatment of bacterial vaginosis (off-label)
Adults: 20 mg orally once daily.
Topical, apply a thin film to affected area once or twice daily.
Terminal elimination half-life: 3-7 hours (mean 4.5 hours). Increased to 8-15 hours in moderate-to-severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
Metformin is excreted unchanged in urine; does not undergo hepatic metabolism or cytochrome P450 metabolism.
Hepatic metabolism via oxidation and glucuronidation. Metronidazole is metabolized by CYP450 enzymes, primarily CYP2A6 and CYP3A4, forming metabolites such as hydroxy metronidazole and acetic acid metabolite.
Primarily renal: 70-80% unchanged drug via glomerular filtration and active tubular secretion; 15-20% biliary/fecal as metabolites.
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein.
Metronidazole: <20% bound to plasma proteins.
Vd: 1.5-2.5 L/kg (mean 2.0 L/kg). Extensive tissue distribution; crosses blood-brain barrier and placenta.
Vd: ~0.6-0.7 L/kg, indicating distribution into total body water.
Oral: 60-75% (due to first-pass metabolism); intramuscular: 90-100%; topical: 10-20% (formulation-dependent).
Topical: Systemic bioavailability approximately 0.1-1% of applied dose for metronidazole 1% cream.
e GFR ≥30 m L/min: no adjustment; e GFR <30 m L/min: 10 mg once daily.
No adjustment required for topical application.
Child-Pugh A: no adjustment; Child-Pugh B: 10 mg once daily; Child-Pugh C: not recommended.
No adjustment required for topical application.
Weight ≥30 kg: 20 mg once daily; weight <30 kg: 10 mg once daily.
Safety and efficacy not established in pediatric patients under 18 years.
≥65 years: initial dose 10 mg once daily, titrate as tolerated.
No specific dose adjustment recommended; use caution due to potential skin atrophy.
Lactic acidosis: Metformin use has been associated with lactic acidosis, a rare but serious metabolic complication. Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years, and hepatic disease.
None
Lactic acidosis risk, impaired renal function (monitor e GFR), vitamin B12 deficiency, acute metabolic acidosis, perioperative use, and concurrent iodinated contrast agents.
Avoid contact with eyes. Use with caution in patients with blood dyscrasias or history of hypersensitivity to metronidazole. Prolonged use may result in overgrowth of non-susceptible organisms. Discontinue if irritation occurs.
Severe renal impairment (e GFR <30 m L/min/1.73 m²), acute metabolic acidosis, severe hepatic disease, and hypersensitivity to metformin.
Hypersensitivity to metronidazole or any component of the formulation.
Avoid high-sodium foods as they may counteract the antihypertensive effect. Consumption of potassium-rich foods (e.g., bananas, oranges) is not restricted unless hypokalemia develops, but monitor potassium levels. Grapefruit juice may increase metolazone absorption; avoid concurrent use. Limit alcohol intake as it may enhance hypotensive effects.
No significant food interactions due to negligible systemic absorption. However, alcohol consumption should be avoided during treatment and for at least 48 hours after discontinuing metronidazole, as trace systemic absorption may cause disulfiram-like reactions (nausea, vomiting, flushing, headache).
METRA is contraindicated in pregnancy due to documented teratogenicity, including neural tube defects, cardiovascular malformations, and craniofacial abnormalities in first trimester. Second and third trimester exposure may cause low birth weight and transient neonatal metabolic disturbances. Use effective contraception during treatment.
Topical metronidazole (Metro Cream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, data do not suggest an increased risk of major malformations; however, use in first trimester is generally avoided due to theoretical risk. For topical application, systemic absorption is minimal (approximately 2%), and the drug is considered safe throughout pregnancy, with no known fetal risks.
METRA is excreted into human breast milk with an M/P ratio of approximately 0.8 to 1.2. Due to potential adverse effects in nursing infants, such as immunosuppression and growth delay, breastfeeding is not recommended during therapy and for 12 months after last dose.
Minimal systemic absorption of metronidazole after topical application (approximately 2%) results in negligible transfer into breast milk. M/P ratio is not established for topical route. Use during breastfeeding is considered compatible; however, avoid application to breast area to prevent infant exposure.
No dosing adjustments are recommended because METRA is contraindicated in pregnancy. In the rare event of inadvertent use during pregnancy, immediate discontinuation is required. Pharmacokinetic changes in pregnancy (increased clearance, reduced protein binding) do not apply as therapy must be ceased.
No dosage adjustment is necessary during pregnancy. Systemic absorption from topical application is minimal and pharmacokinetic changes in pregnancy do not warrant dose modification.
METRA is a brand name for metolazone, a thiazide-like diuretic. Use with caution in severe renal impairment (e GFR <20 m L/min) as effectiveness diminishes. Monitor for hypokalemia, especially when used with loop diuretics. Do not use in hepatic coma or pre-coma.
Metronidazole topical cream is contraindicated in patients with a history of hypersensitivity to metronidazole or other nitroimidazole derivatives. Avoid contact with eyes, mucous membranes, or open wounds. Use during pregnancy only if clearly needed (FDA category B). Warn patients that topical metronidazole may cause transient skin irritation or dryness; if severe, discontinue use. Combine with sunscreen and photoprotective measures due to potential photosensitivity. For rosacea, clinical improvement may take 3–4 weeks; adherence is critical. Do not use with concomitant oral metronidazole or disulfiram-like reactions due to minimal systemic absorption.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,May cause dizziness or lightheadedness due to blood pressure changes; rise slowly from sitting or lying positions.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or extreme thirst.,Do not consume alcohol or take other blood pressure medications without consulting your doctor.
Apply a thin layer to affected areas once or twice daily as directed.,Wash hands before and after application; avoid contact with eyes, mouth, and nostrils.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,May cause mild stinging, burning, or dryness; if severe, stop use and inform your physician.,Minimize sun exposure and use sunscreen daily as metronidazole may increase sun sensitivity.,Notify your doctor if you develop signs of allergic reaction: rash, itching, swelling, or trouble breathing.,Do not use more than prescribed; extended use may lead to bacterial resistance.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before using.,Inform your doctor if you are taking oral metronidazole or have a history of blood disorders or neuropathy.
"Concurrent use of Phenmetrazine, a sympathomimetic amine with central nervous system stimulant activity, and Isoxsuprine, a beta-adrenergic receptor agonist with peripheral vasodilatory effects, may result in additive stimulation of the cardiovascular system. This can lead to synergistic increases in heart rate, myocardial contractility, and blood pressure, potentially precipitating hypertensive crisis, tachycardia, arrhythmias, or myocardial ischemia. Clinically, this interaction poses significant risks for patients with underlying cardiovascular disease, and careful monitoring is essential if concomitant use is unavoidable."
"The combination of Phenmetrazine, a sympathomimetic appetite suppressant, with Oxymetazoline, a direct-acting alpha-adrenergic agonist, can lead to additive vasoconstriction and hypertensive effects. This interaction may precipitate a hypertensive crisis, especially in patients with underlying cardiovascular disease, and can result in adverse outcomes such as myocardial ischemia, stroke, or arrhythmias. Concurrent use should be avoided due to the potential for severe cardiovascular adverse events."
"Amphetamine and phenmetrazine are both central nervous system (CNS) stimulants that increase synaptic norepinephrine and dopamine by promoting release and blocking reuptake. Concurrent use synergistically amplifies adrenergic and dopaminergic signaling, leading to excessive CNS stimulation and cardiovascular strain. This can manifest as severe hypertension, tachyarrhythmia, hyperthermia, agitation, serotonin syndrome-like symptoms, and potentially life-threatening events such as stroke or myocardial infarction."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRA vs METROCREAM, answered by our medical review team.
METRA is a Antibiotic (Nitroimidazole) that works by Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.. METROCREAM is a Antibiotic (Nitroimidazole) that works by Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRA and METROCREAM depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRA is: Adults: 20 mg orally once daily.. The standard adult dose of METROCREAM is: Topical, apply a thin film to affected area once or twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRA and METROCREAM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRA is classified as Category C. METRA is contraindicated in pregnancy due to documented teratogenicity, including neural tube defects, cardiovascular malformations, and craniofacial abnormalities in first trimest. METROCREAM is classified as Category C. Topical metronidazole (MetroCream) is considered low risk for teratogenicity. In animal studies, no evidence of fetal harm was observed at topical doses. For oral metronidazole, da. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.